Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Gross Margin
Guardant Health Inc

60.3%
Current
64%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.3%
=
Gross Profit
417.5m
/
Revenue
692.3m

Gross Margin Across Competitors

Country US
Market Cap 4.3B USD
Gross Margin
60%
Country US
Market Cap 94.1B USD
Gross Margin
11%
Country US
Market Cap 88.8B EUR
Gross Margin
11%
Country US
Market Cap 75.4B USD
Gross Margin
14%
Country DE
Market Cap 24.9B EUR
Gross Margin
25%
Country US
Market Cap 20.2B USD
Gross Margin
28%
Country DE
Market Cap 18.7B EUR
Gross Margin
24%
Country US
Market Cap 18.3B USD
Gross Margin
33%
Country US
Market Cap 13.7B USD
Gross Margin
33%
Country DE
Market Cap 12.5B EUR
Gross Margin
25%
Country AU
Market Cap 13.7B AUD
Gross Margin
84%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.3%
=
Gross Profit
417.5m
/
Revenue
692.3m
What is the Gross Margin of Guardant Health Inc?

Based on Guardant Health Inc's most recent financial statements, the company has Gross Margin of 60.3%.